<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02944097</url>
  </required_header>
  <id_info>
    <org_study_id>HS-VM-2015</org_study_id>
    <nct_id>NCT02944097</nct_id>
  </id_info>
  <brief_title>Bioavailability of Resveratrol From Vineatrol30 Extract Incorporated Into Micelles</brief_title>
  <official_title>Study of the Oral Bioavailability of Trans-epsilon-viniferin and Trans-resveratrol From Native and Micellar Solubilized vineatrol30 Vine Extract</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Hohenheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Hohenheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To enhance the oral bioavailability of the antioxidants trans-resveratrol and
      trans-ε-viniferin from Vineatrol30 grapevine-shoot extract, the native powder was
      incorporated into micelles. A single dose, single blind, two arms crossover trial was
      conducted. Plasma and urine samples were collected at intervals up to 24 h after oral intake
      of native or micellar Vineatrol30 (500 mg), and resveratrol content was quantified and
      compared between formulations. Tolerability of the dose was also controlled by safety
      parameters in plasma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean area under the curve (AUC) of plasma concentration vs. time of total trans-resveratrol [nmol/L*h]</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose</time_frame>
    <description>Total trans-resveratrol after deconjugation with beta-glucuronidase/sulphatase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean area under the curve (AUC) of plasma concentration vs. time of total trans-epsilon-viniferin [nmol/L*h]</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose</time_frame>
    <description>Total trans-epsilon-viniferin after deconjugation with beta-glucuronidase/sulphatase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean maximum plasma concentration (Cmax) of total trans-resveratrol [nmol/L]</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose</time_frame>
    <description>Total trans-resveratrol after deconjugation with beta-glucuronidase/sulphatase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean maximum plasma concentration (Cmax) of total trans-epsilon-viniferin [nmol/L]</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose</time_frame>
    <description>Total trans-epsilon-viniferin after deconjugation with beta-glucuronidase/sulphatase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum plasma concentration (Tmax) of total trans-resveratrol [h]</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose</time_frame>
    <description>Total trans-resveratrol after deconjugation with beta-glucuronidase/sulphatase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum plasma concentration (Tmax) of total trans-epsilon-viniferin [h]</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose</time_frame>
    <description>Total trans-epsilon-viniferin after deconjugation with beta-glucuronidase/sulphatase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative urinary excretion of total trans-resveratrol [nmol/g creatinine]</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose</time_frame>
    <description>Total trans-resveratrol after deconjugation with beta-glucuronidase/sulphatase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative urinary excretion of total trans-epsilon-viniferin [nmol/g creatinine]</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose</time_frame>
    <description>Total trans-epsilon-viniferin after deconjugation with beta-glucuronidase/sulphatase</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum aspartate transaminase activity [U/L]</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum alanine transaminase activity [U/L]</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum gamma-glutamyl transferase activity [U/L]</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum alkaline phosphatase activity [U/L]</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum bilirubin</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum uric acid [mg/dL]</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine [mg/dL]</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum total cholesterol [mg/dL]</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum HDL cholesterol [mg/dL]</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum LDL cholesterol [mg/dL]</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum triacylglycerols [mg/dL]</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL/HDL cholesterol ratio</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum cystatin C [mg/mL]</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular filtration rate [mL/min]</measure>
    <time_frame>0, 4, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum glucose [mg/dL]</measure>
    <time_frame>0, 24h post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Safety After Oral Intake</condition>
  <condition>Pharmacokinetics After Oral Intake</condition>
  <arm_group>
    <arm_group_label>Vineatrol30 native powder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mg Vineatrol30 containing 30 mg trans-resveratrol and 75.2 mg trans-epsilon-viniferin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vineatrol30 micelles</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mg Vineatrol30 micelles containing 30 mg trans-resveratrol and 75.2 mg trans-epsilon-viniferin</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vineatrol 30 native powder</intervention_name>
    <arm_group_label>Vineatrol30 native powder</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vineatrol 30 micelles</intervention_name>
    <arm_group_label>Vineatrol30 micelles</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy Volunteers with blood chemistry values within normal ranges

        Age: 18-35 years

        BMI: 19-25 kg/m2

        Exclusion Criteria:

        Pregnancy or lactation

        Alcohol and/or drug abuse

        Use of dietary supplements or any medications, except contraceptives

        Any known malignant, metabolic and endocrine diseases

        Previous cardiac infarction

        Dementia

        Participation in a clinical trial within the past 6 weeks prior to recruitment

        Smoking

        Physical activity of more than 5 h/wk
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Frank, Prof. Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Hohenheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Hohenheim</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Württemberg</state>
        <zip>70599</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.nutrition-research.de/</url>
    <description>Website of the research group</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2016</study_first_submitted>
  <study_first_submitted_qc>October 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2016</study_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioavailability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>trans-resveratrol</keyword>
  <keyword>trans-epsilon-viniferin</keyword>
  <keyword>Vineatrol 30</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

